- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01403480
Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions
July 26, 2011 updated by: Rambam Health Care Campus
Rates of Positive BCCs in Re-excisions
Basal Cell Carcinoma (BCC) is the most common malignant growth in the world.
Treatment is primarily surgical with the goal of excising the growth in its entirety.
When pathology results show that this has not been achieved, a re-excision is routinely performed.
This study examines retrospectively the percentage of re-excisions of BCC that actually proved to be positive (exhibited growth) among those re-excisions performed at Rambam Healthcare Campus and Zvulun Community Medical Center during the years 2008-10.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
600
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All patients that underwent an incomplete BCC excision during the years 2008-2010.
Description
Inclusion Criteria:
All patients that underwent an incomplete BCC excision during the years 2008-2010.
Exclusion Criteria:
Patients that underwent an incomplete BCC excision and were subsequently referred to undergo a MOHS procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
July 26, 2011
First Submitted That Met QC Criteria
July 26, 2011
First Posted (Estimate)
July 27, 2011
Study Record Updates
Last Update Posted (Estimate)
July 27, 2011
Last Update Submitted That Met QC Criteria
July 26, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0064-11-RMB-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterCompletedBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Daryoush Hamidi Alamdari, PhDEnrolling by invitationInoperable Disease | Advanced Basal Cell Carcinoma (BCC) | Morpheaform Basal Cell Carcinoma | Noduloulcerative Basal Cell Carcinoma | Infiltrative Basal Cell CarcinomaIran
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Christopher ZacharyActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Kirsten JohnsonRecruitingSkin Squamous Cell Carcinoma | Skin Basal Cell Carcinoma | Skin Nodular Basal Cell CarcinomaUnited States
-
Biofrontera Inc.Active, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands